KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 123 filers reported holding KALA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 3.55 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $20,000 | -88.0% | 67,015 | -44.1% | 0.00% | – |
| Q1 2022 | $166,000 | +654.5% | 119,963 | +552.8% | 0.00% | – |
| Q4 2021 | $22,000 | -63.9% | 18,376 | -21.1% | 0.00% | – |
| Q3 2021 | $61,000 | -91.1% | 23,300 | -82.0% | 0.00% | – |
| Q2 2021 | $687,000 | -44.7% | 129,644 | -29.7% | 0.00% | – |
| Q1 2021 | $1,243,000 | +25.8% | 184,383 | +26.5% | 0.00% | – |
| Q4 2020 | $988,000 | +80.6% | 145,800 | +99.9% | 0.00% | – |
| Q3 2020 | $547,000 | -43.8% | 72,953 | -21.3% | 0.00% | – |
| Q2 2020 | $974,000 | +98.8% | 92,738 | +66.5% | 0.00% | – |
| Q1 2020 | $490,000 | – | 55,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 1,890,913 | $43,188,000 | 37.13% |
| CAXTON CORP | 544,220 | $12,430,000 | 12.65% |
| Vivo Capital, LLC | 1,158,911 | $26,470,000 | 5.35% |
| RA Capital Management | 2,113,236 | $48,266,000 | 4.36% |
| Orbimed Advisors | 2,375,279 | $54,251,000 | 0.52% |
| EAM Investors, LLC | 59,218 | $1,353,000 | 0.18% |
| Crestline Management, LP | 38,884 | $888,000 | 0.12% |
| OXFORD ASSET MANAGEMENT LLP | 192,426 | $4,374,000 | 0.08% |
| Eventide Asset Management | 60,000 | $1,370,000 | 0.08% |
| VICTORY CAPITAL MANAGEMENT INC | 543,525 | $12,414,000 | 0.03% |